Your browser doesn't support javascript.
loading
Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019.
Liszkay, Gabriella; Benedek, Angela; Polgár, Csaba; Oláh, Judit; Holló, Péter; Emri, Gabriella; Csejtei, András; Kenessey, István; Polányi, Zoltán; Knollmajer, Kata; Várnai, Máté; Vokó, Zoltán; Nagy, Balázs; Rokszin, György; Fábián, Ibolya; Barcza, Zsófia; Gyulai, Rolland; Kiss, Zoltan.
Afiliación
  • Liszkay G; Department of Molecular Immunology and Toxicology and the National Tumorbiology Laboratory, National Institute of Oncology, Budapest, Hungary.
  • Benedek A; MSD Pharma Hungary Ltd., Budapest, Hungary.
  • Polgár C; Department of Molecular Immunology and Toxicology and the National Tumorbiology Laboratory, National Institute of Oncology, Budapest, Hungary.
  • Oláh J; Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
  • Holló P; Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
  • Emri G; Department of Dermatology, University of Debrecen, Debrecen, Hungary.
  • Csejtei A; Department of Oncoradiology, Markusovszky University Teaching Hospital, Szombathely, Hungary.
  • Kenessey I; Department of Molecular Immunology and Toxicology and the National Tumorbiology Laboratory, National Institute of Oncology, Budapest, Hungary.
  • Polányi Z; MSD Pharma Hungary Ltd., Budapest, Hungary.
  • Knollmajer K; MSD Pharma Hungary Ltd., Budapest, Hungary.
  • Várnai M; MSD Pharma Hungary Ltd., Budapest, Hungary.
  • Vokó Z; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
  • Nagy B; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
  • Rokszin G; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
  • Fábián I; RxTarget Ltd., Szolnok, Hungary.
  • Barcza Z; RxTarget Ltd., Szolnok, Hungary.
  • Gyulai R; University of Veterinary Medicine, Budapest, Hungary.
  • Kiss Z; Syntesia Medical Communications Ltd., Budapest, Hungary.
J Eur Acad Dermatol Venereol ; 37(5): 932-940, 2023 May.
Article en En | MEDLINE | ID: mdl-36785988
BACKGROUND: Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking. METHODS: This nationwide, retrospective study examined melanoma survival in Hungary between 2011-2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex and survival were calculated. RESULTS: Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ±16.39)). Five-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017-2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011-2012 (HR 0.80, 95% CI 0.73-0.89; p < 0.0001). Age-standardized 5-year net survival rates in 2011-2014 and 2015-2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0-39 age cohort (94.6% in the 2015-2019 period). CONCLUSION: Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Diagnostic_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Diagnostic_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Reino Unido